Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc. (LFCR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lfcr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Lifecore Biomedical, Inc. (LFCR) measures how much investors pay for each dollar of the company's trailing earnings. LFCR's current PE ratio of N/A is calculated by dividing its stock price of $5.57 by its TTM earnings per share of -$0.91.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%16.8x
MedianQ3 · 75%132.6x
Max
At N/A, LFCR's current P/E is lower than in 0% of its annual fiscal year readings over the past 13 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lifecore Biomedical, Inc.You LFCR | $209M | N/A | — | -$0.91 |
 Aurora Cannabis Inc. ACB | $202M | 217.84x | — | $0.03 |
 Achieve Life Sciences, Inc. ACHV | $563M | N/A | — | -$1.25 |
 BioAge Labs, Inc. BIOA | $584M | N/A | — | -$2.24 |
 Canopy Growth Corporation CGC | $434M | N/A | — | -$5.56 |
 CVRx, Inc. CVRX | $143M | N/A | — | -$2.04 |
 Immutep Limited IMMP | $54M | N/A | — | -$0.42 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $0.00 | — | |
2025-05-25 FY2025 | — | $-1.11 | — | |
2024-05-26 FY2024 | 14.26x | $0.39 | — | |
2023-05-28 FY2023 | — | $-3.32 | — | |
2022-05-29 FY2022 | — | $-3.96 | — | |
2021-05-31 FY2021 | — | $-1.10 | — | |
2020-05-31 FY2020 | — | $-1.31 | — | |
2019-05-31 FY2019 | 132.57x | $0.07 | +742.7% | |
2018-05-31 FY2018 | 15.73x | $0.90 | -56.7% | |
2017-05-31 FY2017 | 36.35x | $0.39 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lifecore Biomedical, Inc. (LFCR) measures how much investors pay for each dollar of the company's trailing earnings. LFCR's current PE ratio of N/A is calculated by dividing its stock price of $5.57 by its TTM earnings per share of -$0.91.
Frequently asked questions
LFCR pe ratio · 6 questionsLFCR's current PE ratio is N/A as of 2026-06-08, based on a stock price of $5.57 and TTM EPS of -$0.91. Data sourced from Financial Modeling Prep via LFCR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lifecore Biomedical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08